Skip to main content
. 2020 Jan 23;43(3):919–929. doi: 10.3892/or.2020.7478

Figure 4.

Figure 4.

Downregulation of SLCO4C1 affects the proliferation, apoptosis and sphere forming abilities of HEC-1A and RL95-2 cells. (A) The expression of SLCO4C1 in EC cell lines was detected by RT-qPCR. (B) The expression of SLCO4C1 in EC cell lines was detected by western blotting. (C) The expression of SLCO4C1 in HEC-1A and RL95-2 cells transfected with siNC, siSLCO4C1-1 or siSLCO4C1-2 was detected by RT-qPCR analysis. (D) The expression of SLCO4C1 in HEC-1A and RL95-2 cells transfected with siNC, siSLCO4C1-1 or siSLCO4C1-2 was detected by western blotting. (E) Cell proliferation was detected by CCK-8 assay in HEC-1A and RL95-2 cells transfected with siNC, siSLCO4C1-1 or siSLCO4C1-2. (F) Apoptosis analysis of HEC-1A and RL95-2 cells transfected with siNC, siSLCO4C1-1 or siSLCO4C1-2 by flow cytometry. (G) Sphere forming ability of HEC-1A and RL95-2 cells transfected with siNC or siSLCO4C1-1 by sphere-formation assay. (H) Expression of proliferation-related protein Ki67 and apoptotic-related proteins cleaved caspase-3/9 in HEC-1A and RL95-2 cells transfected with siNC, siSLCO4C1-1 or siSLCO4C1-2 by western blotting. GAPDH was used as a loading control. The results were determined from triplicate experiments and the error bars represent the mean ± SD. *P<0.05, **P<0.01, ***P<0.001 vs. the Ctrl group and siNC group. SLCO4C1, solute carrier organic anion transporter family member 4C1; EC, endometrial cancer.